PG
CRL icon

Proffitt & Goodson’s Charles River Laboratories CRL Stock Holding History

Proffitt & Goodson’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1
Closed -$157 – 330
2025
Q3 		$157 Buy
+1
New +$159 ﹤0.01% 440

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Proffitt & Goodson's CRL Position: Q4 2025 in Review

Proffitt & Goodson sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 1 share — an estimated $157 sold.

Proffitt & Goodson first reported a position in CRL in Q3 2025 and held it in 1 quarter. The position peaked at $157 in Q3 2025. 583 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

  • Proffitt & Goodson reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
  • Proffitt & Goodson sold 1 Charles River Laboratories share in Q4 2025, an estimated $157.
  • Proffitt & Goodson first reported a position in Charles River Laboratories in Q3 2025 and held it in 1 quarter.
  • Proffitt & Goodson's Charles River Laboratories position peaked at $157 in Q3 2025.
  • 583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on Proffitt & Goodson's 13F filing for Q4 2025, filed 27 Jan 2026.